Why Tempus paid $1.5bn for Personalis: the data follows the patient

TL;DR

Tempus AI is paying $1.5 billion for Personalis, two months after the FDA approved atezolizumab with Natera's Signatera as companion diagnostic. My read is that Tempus is buying the shape of the data, a record that follows the same patient over time. Personalis is further along than Paige was on making money from a good product, with reimbursement moving. I'm less confident about the timeline, since getting NeXT Personal there means running large trials again, on their own slow clock.

Tempus AI is paying $1.5 billion for Personalis, Inc., two months after the FDA approved atezolizumab for MRD-positive bladder cancer with Natera's Signatera as the companion diagnostic.

Once a ctDNA result decides who gets a drug, MRD has a defined commercial position. Tempus moved fast after that.

What the price is actually buying

Natera ran about 250,000 clinical MRD tests last quarter. Personalis runs somewhere around ten thousand. At $1.5 billion, that price is buying something other than the current business.

My read is that they are buying the shape of the data. Most of what Tempus has assembled gives you one look at a patient: tumor sequencing at diagnosis, pathology since Paige. MRD repeats. Blood draws every few months for years, each one tied to the treatment given and what happened afterward. For a company building models on oncology data, a record that follows the same patient over time is a different input than a profile taken once.

When Tempus bought Paige I wrote that building a good product and finding a way to make money from it are separate problems, and that Paige had only solved the first. Personalis is further along on the second, with reimbursement moving and a category the FDA has now validated in at least one indication.

I'm less confident about the timeline. Signatera ended up in that label because Genentech built it into IMvigor011 years before the readout. Getting NeXT Personal to the same place means running trials of that size again, one indication at a time. That work is slow and expensive, and it runs on its own clock regardless of who owns the company.